From:

Hart, Mary

To:

DeBoer, Briana

Cc:

Roberts, Mark; Ullrich, Elizabeth; Grant, Carl; Ryan Fahey

Subject:

[External_Sender] RE: your email dated June 6, 2018

Date: Attachments: Friday, June 08, 2018 8:10:55 AM Amendment letter June 2018.pdf

Per our phone conversation of 6/6/18, attached please find the response regarding decommissioning activities at the site.

Regards,

Mary

From: DeBoer, Briana < Briana. DeBoer@nrc.gov>

Sent: Wednesday, June 6, 2018 10:50 AM **To:** Hart, Mary <mary.hart@bms.com>

Cc: Roberts, Mark < Mark.Roberts@nrc.gov>; Ullrich, Elizabeth < Elizabeth.Ullrich@nrc.gov>

Subject: your letter dated May 31, 2018

License No. 06-27843-02 Docket No. 030-29266 Control No. 608976

To: Mary C. Hart, RSO, Associate Director, EHS

From: Briana DeBoer, NRC

As discussed on June 6, 2018 via telephone call with Mary Hart, Bristol-Myers Squibb RSO, Ryan Fahey, DDES Project Manager, Mark Roberts, NRC, and Briana DeBoer, NRC, below are the questions we have regarding your request.

- The Decommissioning Plan proposes initiation of decommissioning work the week
 of June 4th, 2018, and PCO-Chemistry is scheduled to stop use of radioactive
 material on July 13, 2018. Please confirm that, as we discussed, decontamination
 activities in the PCO-Chemistry suite will not commence until active work with
 radionuclides has been completed.
- 2. Based on a records review it appears radionuclides from previous license amendments (Chlorine-36 and Nickle-63) are not listed on Table 3.1. Based on our review, please confirm that you have not previously possessed Chlorine-36 and that any Nickle-63 sources, now generally licensed, will be dispositioned in accordance with any applicable requirements in 10 CFR 31.
- 3. Please describe the methodology for disposition of the Cesium-137 source listed on your license?

Thank you,


Briana DeBoer

Health Physicist
Decommissioning, ISFSI, and Reactor Health Physics Branch
USNRC Region 1 DNMS

Rec'd. in LAT-06/11/2018

NMSS/RGNI MATERIALS-002

This message (including any attachments) may contain confidential, proprietary, privileged and/or private information. The information is intended to be for the use of the individual or entity designated above. If you are not the intended recipient of this message, please notify the sender immediately, and delete the message and any attachments. Any disclosure, reproduction, distribution or other use of this message or any attachments by an individual or entity other than the intended recipient is prohibited.



U.S. Pharmaceuticals P. O. Box 5100 Wallingford, CT 06492

June 6, 2018

U.S. Nuclear Regulatory Commission Region 1 2100 Renaissance Boulevard, Suite 100 King of Prussia, PA 19406

Re: Bristol-Myers Squibb License No. 06-27843-02 Amendment

Listed below is the response to your request for additional information regarding the Decommissioning Plan for the Bristol-Myers Squibb facility, located at 5 Research Parkway, Wallingford, CT, 06492.

- Decommission of the active PCO-Chemistry labs will not commence until all work with radionuclides has been completed.
- This Facility has never possessed Chlorine-36.
- The Nickel-63 Gas Chromatograph is no longer in our possession. It was transferred to another facility in 2002.
- The Cesium-137 source listed on our license will be transferred to another BMS facility.

Sincerely,

Mary C. Hart, RSO

Associate Director, EHS

Bristol-Myers Squibb Company

5 Research Parkway

Wallingford, Ct 06492

mary.hart@bms.com

230-677-6071

Carl Grant

Site Director

Bristol-Myers Squibb Company

5 Research Parkway

Wallingford, Ct 06492

carl.grant@bms.com

203-677-7637